Badalona

• Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Ended recruitment
  2023-503812-34-00 4 2019-02-13 Locally Advanced or Metastatic Disease in Solid Tumors
• This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen … Ended recruitment
  2023-510015-19-00 5 2019-02-11 Patients with histologically or cytologically documented muscle-invasi
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo … Ended recruitment
  2022-500254-41-00 5 2018-12-13 Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamou
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat … Ended recruitment
  2024-513912-89-00 10 2018-12-13 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
• An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with … Ended recruitment
  2023-508463-71-00 5 2018-11-30 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus … Ended recruitment
  2024-511365-11-00 5 2018-11-27 Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
• Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended recruitment
  2023-505376-30-00 4 2018-10-30 BRAF V600 mutation–positive unresectable or metastatic melanoma
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year … Ended recruitment
  2024-516905-22-00 5 2018-10-22 Multiple myeloma
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended recruitment
  2024-513206-65-00 5 2018-08-10 resected squamous cell carcinoma of head and neck
• A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re … Ended recruitment
  2023-506861-76-00 5 2018-08-09 Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended recruitment
  2023-508018-41-00 4 2018-07-27 Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
• A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt … Ended recruitment
  2023-509976-40-00 5 2018-05-28 Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended recruitment
  2023-504802-12-00 7 2018-05-16 Lymphoma of B-cell origin
• Talquetamab (GPRC5D and CD3 antibody) in Relapsed or Refractory Multiple Myeloma Ended recruitment
  2023-504581-29-00 7 2018-04-26 Multiple myeloma
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Adv … Ended recruitment
  2024-516477-73-00 3 2018-03-07 Bladder cancer and kidney cancer
• A Phase 3 study to test the AG-120 in combination with Azacitidine in comparison with the use of Azacitidine alone in patients ≥ 18 Years of … Ended recruitment
  2024-514309-73-00 5 2018-02-06 Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
• Darolutamide vs ADT in hormone naïve Pca Ended recruitment
  2024-510840-30-00 4 2017-12-01 Hormone Naive Prostate Cancer
• An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended recruitment
  2023-503438-40-00 7 2017-10-05 Relapsed/Refractory Multiple Myeloma
• A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-ris … Ended recruitment
  2024-513450-30-00 5 2017-09-25 very high risk localized or locally advanced prostate cancer
• A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignancies Ended recruitment
  2024-515119-23-00 9 2017-08-29 Phase Ib and Phase II part 1: HPV-16 positive recurrent or metastatic

Showing 577–600 of 775 trials